Utilized for migraine headaches to alleviate acute symptoms and manage cranial discomfort.
Mechanism of Action
Rizatriptan binds selectively with high affinity to human 5-HT1B and 5-HT1D receptors. This leads to cranial vessel vasoconstriction and inhibition of pro-inflammatory neuropeptide release from trigeminal nerve endings.
Route of Administration
Oral
Onset Time
30–60 minutes
Duration
2–3 hours
Contraindications
Ischemic heart disease, Coronary vasospasm, Uncontrolled hypertension, Concurrent use of MAO inhibitors
Severe Adverse Events
Myocardial infarction, Serotonin syndrome, Stroke — requires immediate medical attention
Common Side Effects
Somnolence, Dizziness, Fatigue
Uncommon Side Effects
Dry mouth, Chest pressure, Nausea
Drug Interactions
Alcohol, MAO Inhibitors, Propranolol, Ergotamine, Fluoxetine
Pregnancy Safety Warnings
FDA Category C: Use only if benefits outweigh risk. Breastfeeding: Excreted in animal milk; compatible with caution.
Age Restrictions
Safety and efficacy established in pediatric patients six years and older.
Information related to Maxalt is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
